MAPK3 and neoplasm: Trametinib, at 0.3 mg·kg−1, only partially inhibited ERK1/2 activation as expected at this submaximal dose in both HCT116 and DLD1 tumours and the addition of AZD0424 did not alter this (Fig. 4D).